New hope for cancer patients with liver issues: experimental drug enters early testing
NCT ID NCT05661461
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an experimental drug called nab-sirolimus in adults with advanced solid tumors who also have moderate liver impairment. The goal is to find a safe dose and see how the drug behaves in the body. About 28 participants will take part to help guide future research.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
START Mountain Region
RECRUITINGWest Valley City, Utah, 84119, United States
-
South Texas Accelerated Research Therapeutics, LLC
RECRUITINGSan Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a new biologic boost standard brain cancer therapy?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?